Key points are not available for this paper at this time.
Programmed death ligand-1 (PD-L1) has been recently adopted for breast cancer as a predictive biomarker for immunotherapies. The cost, time, and variability of PD-L1 quantification by immunohistochemistry (IHC) are a challenge. In contrast, hematoxylin and eosin (H&E) is a robust staining used routinely for cancer diagnosis. Here, we show that PD-L1 expression can be predicted from H&E-stained images by employing state-of-the-art deep learning techniques. With the help of two expert pathologists and a designed annotation software, we construct a dataset to assess the feasibility of PD-L1 prediction from H&E in breast cancer. In a cohort of 3,376 patients, our system predicts the PD-L1 status in a high area under the curve (AUC) of 0.91 - 0.93. Our system is validated on two external datasets, including an independent clinical trial cohort, showing consistent prediction performance. Furthermore, the proposed system predicts which cases are prone to pathologists miss-interpretation, showing it can serve as a decision support and quality assurance system in clinical practice.
Building similarity graph...
Analyzing shared references across papers
Loading...
Shamai et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69dbfaad3e67f8d1386848fd — DOI: https://doi.org/10.1038/s41467-022-34275-9
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Gil Shamai
Amir Livne
António Polónia
SHILAP Revista de lepidopterología
Nature Communications
Technion – Israel Institute of Technology
Carmel Medical Center
Emek Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...